Utilization Of Neoadjuvant Systemic Therapy (Nst) For Breast Cancer
JOURNAL OF CLINICAL ONCOLOGY(2015)
摘要
1027 Background: Multiple clinical trials demonstrated the efficacy of NST to downstage cancers and increase breast conservation. NCCN guidelines recommend NST for clinical stage IIA-IIIA patients who desire breast conservation. Understanding the national patterns of NST use is especially important in light of increasing mastectomy rates. Methods: Women diagnosed 2006-12 were included from the National Cancer Data Base, which contains 70% of incident cancers across the US. Logistic regression was used to examine factors associated with NST use. Results: Among 474,333 women, NST use increased by clinical stage: IIA (15%), IIB (39%), IIIA (52%), and IIIB (77%). Use for inflammatory breast cancer was 89%. NST use also varied by age and receptor status (Table). Mastectomy rates in patients who did not receive NST were: stage IIA (50%), IIB (69%), and IIIA (75%). On multivariable analysis, age, stage and receptor status remained significantly associated with NST. Compared to hormone receptor (HR)+/HER2- patien...
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络